Previous close | 0.4851 |
Open | 0.4852 |
Bid | 0.4800 x 1000 |
Ask | 0.4904 x 1200 |
Day's range | 0.4628 - 0.4901 |
52-week range | 0.3840 - 1.0500 |
Volume | |
Avg. volume | 2,420,143 |
Market cap | 248.986M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
GERMANTOWN, Md., May 13, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 2024.
GERMANTOWN, Md. & CHESTERFIELD, Mo., May 13, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitor (CGM) systems for people with diabetes, in partnership with our global commercial partner, Ascensia Diabetes Care, and St. Louis-based Mercy, a leading health care system and accountable care organization, today announced a first-of-its-kind relationship in a diabetes popu
GERMANTOWN, Md., May 09, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a strategic partnership with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences, and achieve quality objectives for chronic disease management, in the development of its